Vaccitech Says Prime-boost Vaccine Study Data In Women With Low-grade HPV Lesions Is 'Promising Step In Right Direction'

Vaccitech plc VACC announced topline interim data from the HPV001 Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
"These interim data are a promising step in the right direction, and we look forward to seeing the final data in early 2024," said Bill Enright, CEO of Vaccitech.
Data from the first 58 women enrolled who reached their 6-month timepoint in the HPV001 placebo-controlled study were reviewed internally, and the trial will continue as planned to the 12-month primary endpoint.
Also Read: Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens.
Immunogenicity results showed high responses, defined as an average greater than 1,000 spot-forming units per million peripheral blood mononuclear cells in an ELISPOT assay, especially to the E1, E2, and E6 antigens.
VTP-200 was generally well-tolerated with no product-related grade 3 unsolicited events and no product-related SAEs.
These interim data will be presented orally at the upcoming International Papillomavirus Conference in Washington D.C., taking place 17-21 April 2023.
Price Action: VACC shares are down 4.35% at $2.86 on the last check Monday.